News for ORIC Pharmaceuticals, Inc. (ORIC)

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet

**media[550244]**

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients w

On December 31, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving ORIC Pharmaceuticals Inc., reducing its holdings by 1,911,010 sha

**media[535344]**

This is our list of the best health care stocks based on the highest return over the last 30 days.

ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.

**media[525602]**

**media[520495]**

U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Tuesday. Shares of H&E Equipment Services, Inc. HEES rose sharply during Monday's ...

Shares of ORIC Pharmaceuticals, Inc. (ORIC) gained around 8 percent on Monday's regular trading on the Nasdaq and is currently 10 percent higher in the pre-market activity, after the clinical stage oncology company announced that it has entered into a supply agreement with Janssen Research & Development LLC, affiliated to drug major Johnson & Johnson (JNJ), to evaluate ORIC-114.

**media[513592]**

Phase 1b combination trial of ORIC-114 and subcutaneous amivantamab in patients with 1L NSCLC with EGFR exon 20 insertion mutations expected to initiate in Q1

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. ( ORIC), a clinical stage oncology company focused on

**media[505233]**

**media[471316,471319]**

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

The increase in the prevalence of Non-Small Cell Lung Cancer (NSCLC) drives market growth by boosting demand for innovative treatments, and personalized...

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch